What is the current Hemoglobinopathies Treatment Market size?

The Hemoglobinopathies Treatment Market is projected to register a CAGR of 7% during the forecast period (2024-2029) Read More

Who are the key players in Hemoglobinopathies Treatment Market?

Sanofi S.A., Global Blood Therapeutics, Inc., bluebird bio, Inc., EMI Holding, Inc. and Celgene Corporation are the major companies operating in the Hemoglobinopathies Treatment Market. Read More

Which is the fastest growing region in Hemoglobinopathies Treatment Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Hemoglobinopathies Treatment Market?

In 2024, the North America accounts for the largest market share in Hemoglobinopathies Treatment Market. Read More

What years does this Hemoglobinopathies Treatment Market cover?

The report covers the Hemoglobinopathies Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Hemoglobinopathies Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Hemoglobinopathies Treatment Market Trends

Statistics for the 2023 & 2024 Hemoglobinopathies Treatment market trends, created by Mordor Intelligence™ Industry Reports. Hemoglobinopathies Treatment trend report includes a market forecast to 2029 and historical overview. Get a sample of this industry trends analysis as a free report PDF download.

Market Trends of Hemoglobinopathies Treatment Industry

This section covers the major market trends shaping the Hemoglobinopathies Treatment Market according to our research experts:

Sickle Cell Anemia Anticipated to Grow at Significant Rate

Sickle cell anemia refers to the group of blood disorders that cause misshape of red blood cells. This makes difficult for RBC to carry oxygen to different organs and tissues. Poor oxygen in the blood may lead to severe pain syndromes, necrosis and bacterial infections.
The growing number of cases with sickle cell anaemia globally, coupled with the presence of a robust pipeline of drugs for the treatment of disease is anticipated to boost the segment growth over the forecast period.
Drugs used for symptoms of hemoglobinopathies treatment include antibiotics, analgesics, ACE inhibitors. Further, Blood transfusion or stem cell therapy is one of the preferred treatments for hemoglobinopathies. Moreover, increasing research on the treatment of hemoglobinopathies such as gene therapies advancing the market growth.
The World Health Organization has estimated that each year about 300000 babies are born with a severe form of inherited blood disorders, and 5% of the world population carries trait genes for haemoglobin disorders, mainly, sickle cell anaemia and thalassemia. Thus the growing incidence of hemoglobinopathies coupled with the rise in R&D investment for the development of treatment options expected to boost the market over the forecast period.

Hemoglobinopathies Treatment Market Trends

Understand The Key Trends Shaping This Market

Download PDF

Europe is Anticipated to Have Significant Growth

Among the regional segments, Europe is anticipated to have significant market growth over the forecast period. The growth is attributed to a high number of hemoglobinopathies cases especially in Mediterranean countries, new product launches and growing awareness regarding the disorder. North America is anticipated to have notable market growth owing to well-established healthcare infrastructure for early diagnosis and treatment of hemoglobinopathies and initiatives by the government and non-government organizations to increase the awareness.